Page last updated: 2024-11-04

ethyl loflazepate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethyl loflazepate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3299
CHEMBL ID1213460
CHEBI ID31573
SCHEMBL ID156702
MeSH IDM0094367

Synonyms (43)

Synonym
CHEMBL1213460
1h-1,4-benzodiazepine-3-carboxylic acid, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-, ethyl ester
ethyl loflazepate
meilax
victan
cm-6912
loflazepato de etilo [inn-spanish]
ethyl 7-chloro-5-(o-fluorophenyl)-2,3-dihydro-2-oxo-1h-1,4-benzodiazepine-3-carboxylate
loflazepate d'ethyle [inn-french]
cm 6912
einecs 249-489-4
dea no. 2758
loflazepic acid, ethyl ester
brn 0765264
ethyl loflazepate [inn:jan]
ethylis loflazepas [inn-latin]
ethyl fluclozepate
DB01545
meilax (tn)
29177-84-2
D01293
ethyl loflazepate (jan/inn)
ethyl 7-chloro-5-(2-fluorophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepine-3-carboxylate
vjb5fw9w9j ,
unii-vjb5fw9w9j
ethylis loflazepas
5-25-08-00124 (beilstein handbook reference)
loflazepato de etilo
loflazepate d'ethyle
ethyl 7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1h-1,4-benzodiazepine-3-carboxylate
ethyl loflazepate [inn]
ethyl loflazepate [who-dd]
ethyl loflazepate [mart.]
ethyl loflazepate [jan]
ethyl loflazepate [mi]
SCHEMBL156702
ethyl 7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1h-1,4-benzodiazepine-3-carboxylate #
CUCHJCMWNFEYOM-UHFFFAOYSA-N
CHEBI:31573
(e)-ethyl 7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1h-benzo[e][1,4]diazepine-3-carboxylate
Q5404460
DTXSID60865475
ethyl 7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1h-benzo[e][1,4]diazepine-3-carboxylate

Research Excerpts

Overview

Ethyl loflazepate (Victan) is an original 1,4-benzodiazepine (BZD) being used as a potent, nonsedative, minor tranquillizer.

ExcerptReferenceRelevance
"Ethyl loflazepate (Victan) is an original 1,4-benzodiazepine (BZD) being used as a potent, nonsedative, minor tranquillizer. "( Ethyl loflazepate: a prodrug from the benzodiazepine series designed to dissociate anxiolytic and sedative activities.
Bizière, K; Chambon, JP; Dantzer, R; Demarne, H; Hallot, A; Perio, A; Roncucci, R, 1985
)
3.15

Pharmacokinetics

ExcerptReferenceRelevance
" In contrast, elimination half-life and total plasma clearance of the sum of loflazepate + descarboxyloflazepate seemed to be independent of the degree of renal impairment."( Effect of renal failure on the pharmacokinetics of ethyl loflazepate (Victan) in man.
Ba, BB; Berger, Y; Cano, JP; Durand, A; Iliadis, A; Necciari, J, 1989
)
0.53
" Pharmacokinetic data were obtained by measuring the total levels of two of the major metabolites."( Quantitative analysis of CM 6912 (ethyl loflazepate) and its metabolites in plasma and urine by chemical ionization gas chromatography mass spectrometry. Application to pharmacokinetic studies in man.
Cautreels, W; Jeanniot, JP, 1980
)
0.54

Dosage Studied

ExcerptRelevanceReference
" It also may serve in the search for optimum dosage regimens in clinical practice."( Pharmacokinetic modeling of ethyl loflazepate (Victan) and its main active metabolites.
Ba, BB; Cano, JP; Iliadis, A, 1989
)
0.57
" The dose-response curves for both latencies, derived from the maximum prolongation, showed a definite and linear dose-response relationship."( Effects of a new benzodiazepine derivative, ethyl loflazepate (CM6912), on the arousal level of normal humans assessed by the averaged photopalpebral reflex.
Inanaga, K; Isozaki, H; Mizuki, Y; Tanaka, M, 1985
)
0.53
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540237Phospholipidosis-positive literature compound observed in rat
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (54.29)18.7374
1990's4 (11.43)18.2507
2000's4 (11.43)29.6817
2010's6 (17.14)24.3611
2020's2 (5.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.35 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index61.43 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (17.07%)5.53%
Reviews1 (2.44%)6.00%
Case Studies6 (14.63%)4.05%
Observational0 (0.00%)0.25%
Other27 (65.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]